The application from Lykos — a drug enterprise incubated from the Multidisciplinary Affiliation for Psychedelic Research, or MAPS — arrived on the FDA less than a cloud of controversy. Previous trial individuals experienced alleged adverse activities were not reported — including emotions of suicidality once the therapy — and that bias amon… Read More